US EditionPublished • loading... • Updated
House members push for changes in pharmacy-benefit manager pricing, question Trump drug plan
Lawmakers probe secret Trump-era drug pricing deals, questioning if PBMs will lower patient costs or prioritize profits, given their market control.
- On Wednesday, House Energy and Commerce members held a bipartisan hearing to press for transparency on pharmacy benefit managers pricing and the newly launched TrumpRx website.
- Last year, the Trump administration negotiated deals with at least 16 pharmaceutical manufacturers, including Pfizer and AstraZeneca, but experts say almost no deal terms have been disclosed; the TrumpRx website offers coupons for 43 drugs.
- Nearly 80% of the PBM market is controlled by CVS Health, UnitedHealth Group and Cigna, and lawmakers said consolidation raises prices as UnitedHealthcare reimburses its own providers 17% more than independents.
- Rep. Frank Pallone , ranking member, called the secrecy unacceptable and insisted Congress will conduct oversight, while Rep. Morgan Griffith pledged bipartisan efforts to increase transparency without disrupting deals.
- Researchers warned TrumpRx reduces costs for few drugs but most insured patients pay less with insurance, while lawmakers noted private employer‑sponsored insurance premiums will rise 6.5% in 2026 and proposed PBM fiduciary proposals and oversight.
Insights by Ground AI
25 Articles
25 Articles
Watauga Democrat+18 Reposted by 18 other sources
Lawmakers call for drug price transparency, lower costs
(The Center Square) - A bipartisan group of lawmakers on Wednesday called on pharmaceutical companies to provide increased price transparency and lower costs for drugs.
·Calhoun, United States
Read Full Article
House asks for transparency on Trump's 'secret' pharmaceutical deals
House Democrats and Republicans are calling for more transparency on the details of the Trump administration’s deals with pharmaceutical companies, which President Donald Trump has touted as lowering prescription drug prices. Members of the House Energy and Commerce Committee questioned pharmaceutical supply chain experts on Wednesday about whether President Donald Trump’s “Most Favored Nation” deals would lower prices that patients pay at the p…
·Washington, United States
Read Full ArticleCoverage Details
Total News Sources25
Leaning Left2Leaning Right11Center5Last UpdatedBias Distribution61% Right
Bias Distribution
- 61% of the sources lean Right
61% Right
11%
C 28%
R 61%
Factuality
To view factuality data please Upgrade to Premium
